Charles Schwab Investment Management Inc. Has $133,000 Stake in HilleVax, Inc. (NASDAQ:HLVX)

Charles Schwab Investment Management Inc. lowered its position in HilleVax, Inc. (NASDAQ:HLVX) by 66.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,596 shares of the company’s stock after selling 149,271 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.15% of HilleVax worth $133,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BML Capital Management LLC acquired a new stake in HilleVax in the 3rd quarter valued at about $35,000. GSA Capital Partners LLP acquired a new stake in shares of HilleVax in the third quarter valued at approximately $126,000. Maven Securities LTD bought a new position in shares of HilleVax during the 2nd quarter worth approximately $217,000. Algert Global LLC acquired a new position in shares of HilleVax during the 2nd quarter worth approximately $519,000. Finally, Rhumbline Advisers raised its stake in HilleVax by 27.0% in the 2nd quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock valued at $617,000 after acquiring an additional 9,073 shares during the period. Institutional investors and hedge funds own 86.42% of the company’s stock.

HilleVax Price Performance

HLVX stock opened at $1.83 on Friday. HilleVax, Inc. has a one year low of $1.55 and a one year high of $20.22. The stock has a market cap of $91.14 million, a price-to-earnings ratio of -0.59 and a beta of 0.81. The company has a fifty day moving average price of $1.89 and a two-hundred day moving average price of $3.91.

HilleVax (NASDAQ:HLVX) last announced its earnings results on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.10). Research analysts anticipate that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.